H.C. Wainwright analyst Andrew Fein raised the firm’s price target on United Therapeutics (UTHR) to $500 from $400 and keeps a Buy rating on the shares. The firm believes the positive TETON-2 data positions Tyvaso as one of the few late-stage Idiopathic pulmonary fibrosis therapies to deliver consistent benefit across lung function, quality of life, and multiple patient subgroups.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on UTHR:
- United Therapeutics price target raised to $560 from $415 at UBS
- Buy Rating for United Therapeutics: Promising TETON-2 Trial Results Highlight Tyvaso’s Potential in IPF Treatment
- United Therapeutics’ Tyvaso Shines in Phase III Trial, Poised for Growth in IPF Market
- Cautious Optimism for United Therapeutics Amid TETON-2 Success and Market Uncertainties
- United Therapeutics: Hold Rating Amid Positive TETON-2 Results and Competitive Challenges